Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

News SummaryMost relevantAll newsSector newsTweets

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
01:42p ABBOTT LABORATORIES : Earnings Review and Free Research Report: Abbott’s Sales S..
11:45aDJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10:17a ABBOTT LABORATORIES : Reports Third Quarter 2017 Results
10/19 ABBOTT LABORATORIES : Trademark Application for "DHA ARA" Filed by Abbott Labora..
10/19 A GREAT PLACE TO DO GREAT THINGS : Developing Game-Changing Technology at Abbott
10/19 ABBOTT LABORATORIES PAKISTAN : Financial results of Abbott Laboratories Limited ..
10/18 ABBOTT LABORATORIES (NYSE : ABT) reported earnings of $0.66 per share beating Wa..
10/18 ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
10/18 ABBOTT LABORATORIES : tops Street 3Q forecasts
10/18 ABBOTT : Reports Third-Quarter 2017 Results
More news
News from SeekingAlpha
11:42a YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
08:45a I Love Earnings Season! Let's See How Abbott Laboratories, Johnson & Johnson ..
07:37a Buy On Pullback Is A Good Strategy - Cramer's Mad Money (10/19/17)
10/19 ABBOTT LABORATORIES : Quality Deserves A Price, Just Not This Price
10/19 Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
Financials ($)
Sales 2017 27 166 M
EBIT 2017 5 819 M
Net income 2017 2 100 M
Debt 2017 20 334 M
Yield 2017 1,91%
P/E ratio 2017 48,33
P/E ratio 2018 35,54
EV / Sales 2017 4,33x
EV / Sales 2018 3,83x
Capitalization 97 297 M
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 60,8 $
Spread / Average Target 8,6%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372